Immix Biopharma Subsidiary Nexcella, Inc. Announces Additional Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in Relapsed/Refractory AL Amyloidosis Patients, Duration of Response Not Yet Reached
LOS ANGELES, CA, Jan. 06, 2023 (GLOBE NEWSWIRE) — Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (Nasdaq:IMMX) (“ImmixBio”, “Company”, “We” or “Us”) today announced that NXC-201 treatment continues to demonstrate 100% complete responses in a total of 6 relapsed/refractory AL amyloidosis patients. Clinical data published December 2022 in Clinical Cancer Research (https://doi.org/10.1158/1078-0432.CCR-22-0637) demonstrated 100% complete response rate; 100% organ response rate; NXC-201 Duration of Response Not Yet Reached at a median follow-up of 5.2 months (range: 2.5-9.5 months), resulting in a mean 65% reduction (2,656pg/mL) in NT-proBNP from baseline; no grade 4 Cytokine Release Syndrome (CRS); no ICANS neurotoxicity was observed; a 2-stage improvement in NYHA stage was observed. Low-grade CRS duration of median 2 days (range:1-4 days) with median onset on day 2 (range: 1-3 days) points to NXC-201 potentially becoming the first and only out-patient CAR-T to treat AL Amyloidosis and other BCMA-positive malignancies.
Related news for (IMMX)
- Immix Biopharma Attends FDA CEO Forum in Washington DC
- Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
- Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
- Don’t Miss Out: MoBot’s Latest Stock Updates 05/22/25 05:00 PM
- Today’s Top Performers: MoBot’s Market Review 05/22/25 04:00 PM